Androgens in male contraception.


Journal

Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 8 3 2022
medline: 5 10 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Rates of unplanned pregnancies are high globally, burdening women and families. Efforts to develop male contraceptive agents have been thwarted by unacceptable failure rates, side effects and a dearth of pharmaceutical industry involvement. Hormonal male contraception consists of exogenous androgens which exert negative feedback on the hypothalamic-pituitary-gonadal axis and suppress gonadotropin production. This in turn suppresses testicular testosterone production and sperm maturation. Addition of a progestin suppresses spermatogenesis more effectively in men. Contraceptive efficacy studies in couples have shown male hormonal methods are effective and reversible, but also may come with side effects related to sexual desire, acne and serum cholesterol and inconvenient methods of dosing and delivery. Recently, novel androgens as potential contraceptive agents are being evaluated in early clinical trials and look to overcome these drawbacks. Here we summarize landmark studies of prototype male hormonal contraceptives, showcasing recent advances and future prospects in this important area of public health.

Identifiants

pubmed: 35249804
pii: S1521-690X(22)00014-8
doi: 10.1016/j.beem.2022.101627
pii:
doi:

Substances chimiques

Androgens 0
Contraceptive Agents, Male 0
Gonadotropins 0
Progestins 0
Testosterone 3XMK78S47O
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

101627

Subventions

Organisme : NICHD NIH HHS
ID : HHSN275201300025I
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest STP: One-time consultant for Clarus Therapeutics. AT: Nothing to disclose.

Auteurs

Arthi Thirumalai (A)

Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. Electronic address: arthidoc@uw.edu.

Stephanie T Page (ST)

Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. Electronic address: page@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH